Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07650383
PHASE1

A Study to Evaluate ENERGI-F705 Tablets in Healthy Volunteers

Sponsor: Energenesis Biomedical Co., Ltd.

View on ClinicalTrials.gov

Summary

To evaluate the safety, the tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of ENERGI-F705 Tablets in healthy subjects.

Official title: A Phase I, Double-Blinded, Randomized, Vehicle-Controlled, and Single-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ENERGI-F705 Tablets in Healthy Volunteers

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2025-02-24

Completion Date

2025-11-19

Last Updated

2026-06-16

Healthy Volunteers

Yes

Interventions

DRUG

ENERGI-F705 Tablets 60 mg

ENERGI-F705 tablets administered orally under fasting conditions.

DRUG

ENERGI-F705 Tablets 120 mg

ENERGI-F705 tablets administered orally under fasting conditions.

DRUG

Vehicle Control

Matched vehicle control tablets administered orally under fasting conditions.

Locations (1)

Taipei Medical University Hospital

Taipei, Taiwan